Search results
Results from the WOW.Com Content Network
Fluorouracil (5-FU, 5-fluorouracil), sold under the brand name Adrucil among others, is a cytotoxic chemotherapy medication used to treat cancer. [3] By intravenous injection it is used for treatment of colorectal cancer , oesophageal cancer , stomach cancer , pancreatic cancer , breast cancer , and cervical cancer . [ 3 ]
5-Fluorouracil (5-FU), the nucleobase of doxifluridine, is currently an FDA-approved antimetabolite. [2] 5-FU is normally administered intravenously to prevent its degradation by dihydropyrimidine dehydrogenase in the gut wall. Doxifluridine is a fluoropyrimidine derivative of 5-FU, thus a second-generation nucleoside prodrug.
In the Nigro protocol, the patient receives 30 Gy (3000 rads) of radiation over a three-week period, as well as continuous administration of fluorouracil for the first four days and on days 20–31, with bolus mitomycin on day 1. [3] It is named after Norman Nigro (1912–2009), [4] who developed it in the mid-1970s. [5]
FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer.It is made up of the following drugs: [1] FOL – folinic acid (), a vitamin B derivative with multiple applications, which in this context decreases the cytotoxicity of 5-fluorouracil;
The dose schedule given every two weeks is as follows: [5] Day 1–2: Oxaliplatin 100 mg/m 2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m 2 (or levoleucovorin 200 mg/m 2) IV infusion, followed by 5-FU 400 mg/m 2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m 2 for first two cycles, and may be increased to 3000 mg/m 2 if tolerated by ...
Tegafur/uracil (abbreviation: UFT [1]) is a chemotherapy drug combination used in the treatment of cancer, primarily bowel cancer.. UFT is an oral formulation combining uracil (a competitive inhibitor of dihydropyrimidine dehydrogenase), and tegafur (a bioavailable 5-fluorouracil (5-FU) prodrug) in a 4:1 molar ratio.
In the intent-to-treat cohort population, the median overall survival rate was 7.92 months in the CM24 combo treatment arm versus 5.55 months in the chemo arm. The median progression-free survival ...
Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. [4] It belongs to the class of medications known as fluoropyrimidines, which also includes 5-FU and tegafur. [5] Capecitabine was patented in 1992 and approved for medical use in 1998. [6] It is on the World Health Organization's List of Essential ...